Anthonius de Boer

Also affiliated with University of Nusa Cendana, Pharmo Institute, Universitas Nusa Nipa Maumere, Medicines Evaluation Board

Economics, Econometrics and FinancePharmacology, Toxicology and PharmaceuticsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention”.

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention

Genes(2020)10.3390/genes11091068

N/A

0.414DataRank · unranked

6 citations

Alfi Yasmina, Gerrit J.A. Vos, Paul W.A. Janssen, Christian M. Hackeng, Johannes C. Kelder +10 more

A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines

Journal of Clinical Epidemiology(2019)10.1016/j.jclinepi.2019.06.007

N/A

0.330DataRank · unranked

8 citations

Cristina Avendaño-Solà, Anthonius de Boer, Stephan K. James, Frits R. Rosendaal, Richard Stephens +4 more